We have previously described a series of monoclonal 
Introduction
Glycoproteins IIb (GP IIb)' and IIIa (GP IlIa) form a major heterodimeric complex in platelet membranes that is involved in fibrinogen binding and platelet aggregation (1) (2) (3) (4) (5) (6) (7) (8) . In addition, the GP I~b-IIla complex appears to be a site for the binding of Factor VIII and fibronectin to thrombin-stimulated platelets (9) (10) (11) and may also provide a site for the binding of the cytoskeletal protein network to the platelet membrane (12) . Absence or decreased amount of the platelet GP Ilb-IIa complex characterizes the inherited bleeding disorder thrombasthenia, and platelets from thrombasthenic patients show decreased fibrinogen binding and impaired aggregation (1-8, 12, 13) .
Platelets and their parent cells, the megakaryocytes, appear to share several characteristics with vascular endothelial cells. Both synthesize Factor-VIII-related antigen (14, 15) ; in addition, endothelial cells have been shown to synthesize fibrinectin (16) (17) (18) , thrombospondin (19, 20) , a mitogenic factor for smooth muscle (21) , and Factor V (22) , all of which are also present in platelets. Furthermore, both cell-.types have binding sites for thrombin (23) (24) (25) and Factor Xa (26, 27) and provide an effective surface for prothrombin activation (26, 27) . We used monoclonal antibodies against human platelet GP I11a to show the presence of a platelet GP-IIIa-related protein in human endothelial cell membranes.
Methods
Silicone oils (methylsilicone DC 200 and diphenylsilicone DC 550) were purchased from William F. Nye, Inc., Fairhaven, MA. Nonidet P40 (NP40) was purchased from Particle Data, Inc., Elmhurst, IL.
Na'25I was obtained from Cambridge Nuclear Corp., Billerica, MA. Protein A Sepharose was obtained from Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, NJ. Sodium dodecyl sulfate (SDS) and iodogen were obtained from Pierce Chemical Co., Rockford, IL. Acrylamide, molecular weight standards for electrophoresis, Tween 20, Affigel 10, and Bio-Gel A-SM were purchased from Bio-Rad Laboratories, Richmond, CA. Bovine albumin (fraction V), heparin (sodium salt, grade I from porcine intestinal mucosa, 168 U/mg), leupeptin, benzamidine, and phenylmethylsulfonylfluoride (PMSF) were obtained from Sigma Chemical Co., St. Louis, MO. Phosphorylase B (methyl-14C) was obtained from New England Nuclear, Boston, MA. Standard laboratory chemicals were purchased from Fisher Scientific Co., Allied Corp., Pittsburgh, PA. Tissue culture medium, bovine fetal serum, gelatin, and trypsin were obtained from Gibco Laboratories, Grand Island, NY. Endothelial cell growth factor (ECGF) was prepared as described before (28) . Platelets were obtained from two patients with thrombasthenia (N.M. and M.M.) who have been described previously (29 (30) . F(ab')2 fragments were prepared by pepsin digestion followed by removal of intact IgG by protein A Sepharose as described previously (31) . The purified antibodies were labeled by the chloramine T method (32) at 1,500-4,000 Ci/mM sp act (2,000-5,000 cpm/ng).
Preparation of platelets. Blood from normal volunteers and from the two patients with thrombasthenia was collected into 1:9 vol of 3.8% trisodium citrate. Platelet-rich plasma was obtained by centrifugation at 150 g for 15 min at room temperature. It was then centrifuged at room temperature for 10 min at 2,000 g. The platelet pellet was resuspended in a washing buffer consisting of 0.15 M NaCl, 0.02 M Tris, 2 mM EDTA, 5 mM dextrose, and 1 mg/ml albumin, pH 7.5, and washed three times in this buffer by sedimentation. For binding studies, the platelet button was suspended in pH 7.5 buffer containing 0. 15 Two cloned endothelial cell strains, derived from human umbilical vein (HUVE-12M) and human aorta (HAAE-1F), were used. The cloned cells had undergone 30 cumulative population doublings in culture at the time of these studies. In addition, cultured human endothelial cell lines derived from internal iliac artery (HIAE-25) and inferior vena cava (HIVCE-17) were used in electrophoretic studies. These cells had undergone 3 and 10 cumulative population doublings, respectively, at the time of the studies. The cloned endothelial cell strains were used in binding studies (HUVE-12M), in surface labeling with 1251 (HUVE-12M), and in metabolic labeling with [35Sjmethionine (HAAE-1F). All the cell lines were used in immunoblotting studies. Human aortic smooth muscle cells were used as negative controls in immunoblotting studies.
Binding studies. Suspensions of 200 t1 platelets (3 X 108/ml) or 200 ,l HUVE cells (106/ml) were incubated for periods of 2-120 min with each monoclonal antibody at room temperature or at 4°C in 500-Mgl Eppendorf tubes. After incubation the tube contents were layered onto silicone oil in micro-Eppendorf centrifuge tubes (Fisher Scientific Co., Allied Corp.) and spun at 10,000 g for 2 min at room temperature in an Eppendorf model 3200 centrifuge (Fisher Scientific Co., Allied Corp.). The pellet and supernatant were counted separately in an Isodyne gamma counter (model 1185; G. D. Searle & Co., Chicago, IL). For dose response curves, various concentrations (0.01-10 Mg/ml) of labeled antibody were incubated with endothelial cells or platelets for 10 min. "Nonspecific" binding was measured at a 100-fold excess of unlabeled antibody and subtracted from the total bound to give "specific" binding. In addition, a monoclonal anti-T-cell antibody, B66.7, that does not react with endothelial cells, as shown by indirect radioimmunoassay and western blotting, was labeled and used as a negative control in the binding studies. Specific binding was analyzed according to the method of Scatchard, as described previously (5 at a concentration of 2 X 106/ml. An aliquot (500 gd) of the cell suspension was radioiodinated with 2 mCi of Na'25I by the iodogen method (36) . The reaction was terminated by washing the cells three times in cold phosphate-buffered saline containing 1 mM PMSF. After the final wash the pellet was lysed by suspension in I ml of the lysing buffer for 30 min on ice with occasional vortexing. The lysate was centrifuged at 10,000 g for 10 min at 4°C in Eppendorf centrifuge, and the supernatant stored at -70°C.
Affinity chromatography. The monoclonal antibody B2. 12 was coupled to Affigel 10, using 55 mg of antibody for 5 ml of gel (37) . Washed platelets (1 X 10") were disrupted by sonication in a sonicator (Branson Sonic Power Co., Danbury, CT) and centrifuged at 10,000 g for 1 h at 4°C (model L3-50 ultracentrifuge, Beckman Instruments, Inc., Palo Alto, CA). The membrane proteins were solubilized in the lysing buffer, "precleared" by passage through a 1 X 4-cm column of normal mouse IgG coupled to Affigel 10, and then applied to the immunoaffinity column. Bound proteins were eluted with 0.05 M diethylamine and 1% NP40, pH 11.5, as described by Parham (38) . The eluate was immediately neutralized with 1:20 vol of 1 M Tris, pH 7.5, and dialyzed at 4°C against lysing buffer. In some experiments solubilized platelet membranes were mixed with solubilized radiolabeled endothelial cells, and the mixture subjected to affinity chromatography.
Metabolic labeling. HAAE-IF were grown to confluence as described above and washed in methionine-free medium 199. Fresh methioninefree medium 199, containing ECGF, heparin, fetal calf serum, and 500 MCi [35S]methionine (Amersham Corp., Arlington Heights, IL) was added. After 24 h of incubation, the medium was removed, and the cells were washed and then solubilized in the lysing buffer and subjected to affinity chromatography as described above. The cells and eluate were subjected to SDS-PAGE (7%), and proteins were identified by fluorography (18) .
Polyclonal antibody against GP IIIa. The platelet GP Ilb-IIIa complex was isolated by immunoaffinity chromatography, and the isolated complex was subjected to SDS-PAGE in 7% gels. The bands representing GP Ilb and GP IlIa were identified by staining for 15 min with 0.25% Coomassie blue in 50% methanol/0.5% acetic acid for 2 h. The transverse strips containing GP IlIa were cut out and chopped into pieces and eluted by agitating in 0.125 M Tris, 0.1% SDS, and 1 mM PMSF overnight at room temperature. The eluted proteins were injected into rabbits weekly for 6 wk. Rabbit serum was heat-inactivated and absorbed with platelets from a patient with Glanzmann's thromboasthenia (1 X 109 platelets/ml of serum). Ouchterlony double immunodiffusion was performed in 1% agarose (Seakem ME; FMC Corp., Rockland, ME), 0.15 M NaCl, and 0.02 M Tris, pH 7.5, containing 1% (vol/vol) Triton X-100. The wells contained solubilized platelets (108/ml), or endothelial cells (106/ml), or 10 itg of affinity-purified platelet GP Illa.
Results
Binding of monoclonals to platelets. As previously described (30), monoclonal antibodies B2.12 and B59.2 bind to platelets saturably. Binding was complete within 2 min and was completely reversible in the presence of a 100-fold excess of cold antibody. At saturation -21,000 binding sites were detected on the platelet surface with B2.12 and B59.2. The extent of binding was the same in stimulated and unstimulated platelets and was unaffected by the presence of 5 mM Ca"+ or 5 mM EDTA. In two patients with thrombasthenia, binding with B2. 12 was 10% of normal and with B59.2 '-5% of normal. The immunologic specificity of these two antibodies was further characterized by a combination of SDS-PAGE and western blotting; both B2. 12 and B59.2 detected a single protein in solubilized platelet membranes with an apparent molecular weight of 95,000 (Fig. 1) . When electrophoresis was performed in the presence of reducing agents, this protein showed the increase in molecular weight characteristic of GP i11a, but samples run in this manner showed greatly reduced antigenic activity in western blots.
Binding of monoclonals to endothelial cells. When endothelial extracts were examined for reactivity against these monoclonal antibodies by SDS-PAGE and western blotting, B2. 12 identified a single protein with a molecular weight similar to, but not identical with, that of platelet GP IIIa (Fig.  2) . In contrast to the finding in platelets, however, monoclonal B59.2 did not react with these endothelial cell extracts. Identical results were obtained with endothelial cells detached from culture plates by enzymatic and nonenzymatic means. Neither B2.12 nor B59.2 reacted with human aortic smooth muscle cell extracts under similar conditions. As shown in Fig. 3 endothelial cells as well as with solubilized platelets, giving a line of identity (Fig. 4) .
Affinity chromatography. We attempted to purify the endothelial cell GP-IIIa-related protein by affinity chromatography on a B2. 12 Affigel column, a technique similar to the one we employed for platelets. However, when endothelial cells were used we had great difficulty in purifying detectable amounts of protein. We therefore labeled endothelial cells with 125I, prepared NP40 extracts, mixed them with unlabeled platelet membranes, and applied the mixture to the B2. 12 immunoaffinity column. Under these conditions, both GP lib and GP IIIa were isolated from platelets (Fig. 5 A) , while an autoradiograph of the same gel revealed the presence of only a single protein from endothelial cells whose molecular weight was slightly higher than that of platelet GP i11a (Fig. 5 B) . The decreased mobility on reduction characteristic of platelet GP Ifla was less apparent for the endothelial cell protein (Fig. 5  B) . The 40,000-mol-wt protein seen in Fig. 5 A, lanes 2 and 3, co-migrated with actin.
Synthesis of GP Ilfa-like protein by cultured endothelial cells. HAAE-IF in culture incorporated [35S]methionine into several proteins (Fig. 6) . After immunoaffinity chromatography of solubilized endothelial cells on a column of platelet GPIIIa-specific monoclonal B2.12, we obtained a radiolabeled 5) . Further studies will be necessary to delineate the structural differences between this protein, which we shall term EC GP IIIa, and platelet GP IlIa. Is EC GP ila complexed with a GP-IIb-like protein, as in platelets, or possibly with some other protein? Our preliminary data suggest not. Firstly, a monoclonal antibody against platelet GP Ilb (gift of Dr. R. P. McEver, University of Texas, San Antonio) did not bind to endothelial cells. Secondly, no stoichiometric amounts of GP IIb or any other protein could be detected after GP IIIa immunoaffinity chromatography of endothelial cell extracts under conditions that, as we have already mentioned, always resulted in the appearance of GP IIb in the eluate from solubilized platelets.
GP-IIIa-related protein may be present in other cell types besides endothelial cells and platelets. Thus, Newman et al. (44) recently reported that one GP-IIIa-specific monoclonal antibody raised against platelets reacted with monocytes and neutrophils. In addition, Gogstad et al. (45) , using polyclonal antibodies against the platelet GP IIb-IIIa complex, observed an immunoprecipitin reaction in crossed antigen-antibody electrophoresis of Triton X-100-solubilized monocytes. Neither B2.12 nor B59.2 bound to monocytes or neutrophils or to human aortic smooth muscle cells. However, our plateletspecific antibodies were initially selected on the basis of, among other properties, lack of reactivity toward other circulating blood cells. Thus, the possibility of GP-IIIa-related epitopes being common to platelets and monocytes or neutrophils cannot be completely excluded by our data.
The possible physiologic function of EC GP Illa is not known. In stimulated platelets GP IIIa appears to be the site of fibrinogen binding, although this binding seems to require the presence of GP Ilb as well (2) . In addition, the GP IIb-IIIa complex was involved in Factor VIII antigen and fibronectin binding to thrombin-stimulated platelets, although the individual roles of the components of this complex have not been investigated. The presence of a GP IIIa-like protein in endothelial cells may endow these cells with some of the same binding properties. Preliminary experiments performed by us and others (46) suggest that fibrinogen may bind to endothelial cells. Studies are currently in progress in our laboratory to define more exactly the structure of EC GP Ila and to investigate its possible role in the binding of fibrinogen, fibronectin, and Factor VIII to endothelial cells.
